Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QNWR | ISIN: US8808811074 | Ticker-Symbol: 430
Tradegate
31.03.25
14:36 Uhr
2,640 Euro
-0,060
-2,22 %
1-Jahres-Chart
TERNS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
TERNS PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,6002,64020:05
2,6002,64020:02

Aktuelle News zur TERNS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
21.03.Terns Pharmaceuticals (NASDAQ:TERN) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS2
20.03.Terns Pharmaceuticals GAAP EPS of -$0.24 beats by $0.072
TERNS PHARMACEUTICALS Aktie jetzt für 0€ handeln
20.03.Terns Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
20.03.Terns Pharmaceuticals, Inc. - 10-K, Annual Report1
20.03.Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates92Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 First patient enrolled in Phase...
► Artikel lesen
25.02.Terns Pharmaceuticals reports progress in clinical trials9
24.02.Terns Pharmaceuticals appoints new CFO to bolster growth17
24.02.Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer127FOSTER CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule...
► Artikel lesen
20.02.Terns Pharmaceuticals, Inc. - 8-K, Current Report1
06.02.Terns Pharmaceuticals, Inc. - 8-K, Current Report2
03.02.Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)47FOSTER CITY, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule...
► Artikel lesen
02.01.Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)100FOSTER CITY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule...
► Artikel lesen
03.12.24Terns reports positive early results in CML drug trial6
03.12.24Terns meldet positive erste Ergebnisse in CML-Medikamentenstudie14
03.12.24Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia132Compelling molecular responses starting at lowest dose level in heavily pre-treated patients with high baseline BCR-ABL transcript levels Encouraging safety profile with no dose limiting toxicities...
► Artikel lesen
03.12.24Terns Pharmaceuticals, Inc. - 8-K, Current Report-
02.12.24Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)83FOSTER CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule...
► Artikel lesen
18.11.24Terns Pharmaceuticals appoints new board member3
18.11.24Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors1
18.11.24Terns Pharmaceuticals, Inc. - 8-K, Current Report-
Seite:  Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2